An artificial-intelligence approach created at Carolina could help bring new drugs to patients quicker.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.
Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week.
“If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new ‘words,’ or molecules,” said Tropsha. “If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones.”
ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.
“A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu,” said Isayev. “We want to give scientists a grocery store and a personal chef who can create any dish they want.”
The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles.The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.
“The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials,” said Tropsha.
The Latest on: Drug design
via Google News
The Latest on: Drug design
- Nanoscope Therapeutics Receives Orphan Drug Designation for gene therapy of blindnesson January 25, 2021 at 10:04 am
NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy, today announced that it has received an Orphan drug designation from FDA ...
- 'Life-changing' drug gives Welsh student Izzy a new outlook on living with Cystic Fibrosison January 25, 2021 at 9:25 am
The Cardiff student has started blogging about her experiences in the hope of helping others with the condition.
- Drug Trafficking, Politics and Power: The Lost Territorieson January 25, 2021 at 8:30 am
How a new generation of global drug lords emerged at the end of the 1970s, in want of both money and power. From colonial China’s opium wars to Cold War US politics, we trace rise of global drug trade ...
- Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibaton January 25, 2021 at 5:24 am
Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designations - - ...
- Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-drug Conjugateon January 25, 2021 at 1:15 am
Piramal Pharma Solutions (PPS) is providing drug product formulation and manufacturing from the company's Lexington, KY site in the U.S.- Drug ...
- Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a ...on January 21, 2021 at 10:20 pm
UX701 manufacturing complete at commercial quality and scale using HeLa PCL technology NOVATO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a ...
- Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claimson January 21, 2021 at 11:11 am
An unusual experiment to prevent nursing home staff members and residents from infection with the coronavirus has succeeded, the drug maker Eli Lilly announced on Thursday. A drug containing ...
- Sygnature Discovery Adopts OpenEye Scientific's Orion™ Platform to Strengthen Molecular Design Serviceson January 21, 2021 at 5:00 am
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced ...
- Our Investment in Plexium: Bringing Intelligent Design to Therapeutic Protein Degraderson January 20, 2021 at 4:00 pm
When James Marshall discovered the first flake of gold at Sutter’s Mill in 1848 that set off the California Gold Rush, the only tools available to continue his search were simple pans and sluices - ...
via Bing News